ICER’s Migraine Report Tells Familiar Story
It’s a new drug, but the same old story. The Institute for Clinical and Economic Review recently reported that preventive treatments for migraine may not, in their interpretation, be cost effective. Known as CGGRP inhibitors, the drugs offer patients and health care providers the chance to not just treat but prevent debilitating migraine headaches.
What’s Missing from ICER’s Analysis of Migraine Therapies?
The Institute for Clinical and Economic Review says new CGRP inhibitor treatments for chronic and episodic migraine probably won’t be cost effective. But the analysis omits five important components. View the Graphic
Feedback on CGRP Inhibitors as Preventive Treatments for Patients with Migraine
Migraine is one of the most prevalent neurological disorders worldwide, associated with substantial health, sociological and economic consequences. Yet ICER’s draft evidence report, dated April 11, 2018, inaccurately assesses the benefits that migraine patients can receive from CGRP inhibitors. This inaccuracy arises because: (1) the evidence that is necessary to evaluate the cost-effectiveness of CGRP […]
New Resources Remind Moms-to-Be of Seafood Benefits
Raw sushi is out, and fish oil supplements are questionable. But regular fish consumption as part of a healthy prenatal diet? That’s a surefire way for pregnant women to realize health benefits for themselves and their babies.
Are Americans Aware of COPD?
Many Americans felt like they knew former first lady Barbara Bush, whose death the country mourned this month. But how much do we as a nation know about the disease that killed her?
ICER Case Study: Migraine
Migraine is one of the most prevalent neurological disorders worldwide, associated with substantial health, sociological, and economic consequences. The current treatment options for migraine are medicines that were developed for other diseases, such as hypertension, depression, and epilepsy. During the last decade, however, new medicines have been developed to explicitly target the causes of migraine. […]
Parkinson’s Patients Face Treatment Delays
During a recent visit with one of my Parkinson’s patients, we decided he was a good candidate for deep brain stimulation. The treatment can help relieve severe tremors, stiffness and slowness, hallmarks of the disease. But when my patient’s health insurer got involved, what should have been a straightforward treatment got unnecessarily complicated.
Innovation, Access Issues Dominate Biologics & Biosimilars Summit
“I thought maybe I wasn’t very good athletically.” That was iconic Olympic gold medalist Jackie Joyner-Kersee’s recollection of her first experience with asthma attacks.
Cost Sharing is Costing Skin Patients their Medication
After spending time and money to see a dermatologist, many patients with acne fail to fill their prescription. Cost sharing is the culprit, according to a recently published study.
FDA Opens Door to Pregnant Women in Clinical Trials
Nearly 4 million babies are born each year in the United States. Yet physicians can have remarkably limited data about treating mothers’ health conditions during pregnancy.
